IP Library Granted Patent US 10,648,020
Granted Patent B2
US 10,648,020 · App. 15/844,608 · Granted May 12, 2020

CRISPR enzymes and systems

Inventors: Feng Zhang (Cambridge, MA); Bernd Zetsche (Gloucester, MA); Jonathan S. Gootenberg (Cambridge, MA); Omar O Abudayyeh (Boston, MA); Ian Slaymaker (Cambridge, MA)
Assignees: THE BROAD INSTITUTE, INC.; MASSACHUSETTS INSTITUTE OF TECHNOLOGY; PRESIDENT AND FELLOWS OF HARVARD COLLEGE
C12Q1/6832C12N9/22C12N15/11C12N15/113C12Q1/6816C12N2310/20C12N2800/80
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,648,020
App. No.
15/844,608
Granted
May 12, 2020
Kind
B2
Abstract

The invention provides for systems, methods, and compositions for targeting nucleic acids. In particular, the invention provides non-naturally occurring or engineered DNA-targeting systems comprising a novel DNA-targeting CRISPR effector protein and at least one targeting nucleic acid component like a guide RNA. Methods for making and using and uses of such systems, methods, and compositions and products from such methods and uses are also disclosed and claimed.

Claims (17)

1. A method for detecting a target DNA in a eukaryotic nucleic acid sample, comprising:

(a) contacting the nucleic acid sample with a CRISPR-Cpf1 complex comprising a Cpf1 effector protein and a guide polynucleotide that comprises a guide sequence linked to a direct repeat sequence, wherein the guide sequence directs sequence-specific binding of the CRISPR-Cpf1 complex to the target DNA, and wherein the complex lacks a tracr sequence; and

(b) detecting presence of the target DNA by detecting occurrence of binding of the CRISPR-Cpf1 complex to the target DNA or cleavage of the target DNA by the CRISPR-Cpf1 complex.

2. The method of claim 1 , wherein the Cpf1 effector protein is of a bacterial species selected from the group consisting of Francisella tularensis 1 , Francisella tularensis subsp. novicida, Prevotella albensis, Lachnospiraceae bacterium MC2017 1 , Butyrivibrio proteoclasticus, Peregrinibacteria bacterium GW2011_GWA2_33_10 , Parcubacteria bacterium GW2011_GWC2_44_17 , Smithella sp. SCADC, Acidaminococcus sp. BV3L6 , Lachnospiraceae bacterium MA2020 , Candidatus Methanoplasma termitum, Eubacterium eligens, Moraxella bovoculi 237 , Leptospira inadai, Lachnospiraceae bacterium ND2006 , Porphyromonas crevioricanis 3 , Prevotella disiens and Porphyromonas macacae.

3. The method of claim 1 , wherein the Cpf1 effector protein is Acidaminococcus sp. BV3L6 Cpf1 (AsCpf1), Lachnospiraceae bacterium ND2006 Cpf1 (LbCpf1), or Franscisella novicida U112 Cpf1 (FnCpf1).

4. The method of claim 3 , wherein the Cpf1 effector protein is Franscisella novicida U112 Cpf1.

5. The method of claim 3 , wherein the Cpf1 effector protein is Acidaminococcus sp. BV3L6 Cpf1.

6. The method of claim 3 , wherein the Cpf1 effector protein is Lachnospiraceae bacterium ND2006 Cpf1.

7. The method of claim 1 , wherein the occurrence of binding of the CRISPR-Cpf1 complex to the target DNA or cleavage of the target DNA by the CRISPR-Cpf1 complex is detected by a fluorescent signal.

8. The method of claim 1 , wherein the target DNA is associated with a disease.

9. The method of claim 1 , wherein the target DNA is associated with cancer.

10. The method of claim 1 , wherein the target DNA is associated with a virus.

11. The method of claim 1 , wherein the target DNA comprises a target sequence hybridizable with the guide sequence, wherein the target sequence is located at 3′ of a Protospacer Adjacent Motif (PAM).

12. The method of claim 11 , wherein the PAM comprises a 5′ T-rich motif.

13. The method of claim 11 , wherein the PAM sequence is TTN, where N is A/C/G or T and the effector protein is FnCpf1, or wherein the PAM sequence is TTTV, where V is A/C or G and the effector protein is PaCpf1, LbCpf1 or AsCpf1.

14. The method of claim 1 , wherein the nucleic acid sample is obtained from a human subject.

15. The method of claim 1 , wherein the nucleic acid sample is contacted with the CRISPR-Cpf1 complex in vitro.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 23, 2020
From: ZHANG, FENG
To: THE BROAD INSTITUTE, INC.; MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Reel/Frame 053854/0090 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 23, 2020
From: ZETSCHE, BERND
To: THE BROAD INSTITUTE, INC.
Reel/Frame 053854/0223 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 23, 2020
From: ABUDAYYEH, OMAR O.
To: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Reel/Frame 053854/0309 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 23, 2020
From: SLAYMAKER, IAN
To: THE BROAD INSTITUTE, INC.
Reel/Frame 053854/0419 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 26, 2019
From: GOOTENBERG, JONATHAN S.
To: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Reel/Frame 050160/0255 →
Priority Claims (1)
EP 16150428 · Jan 7, 2016 · regional
Continuity (8)
Continuation In Part PCTUS2016038181 · Jun 17, 2016
Continuation In Part 14975085 · Dec 18, 2015
Provisional Application 62181739 · Jun 18, 2015
Provisional Application 62193507 · Jul 16, 2015
Provisional Application 62201542 · Aug 5, 2015
Provisional Application 62205733 · Aug 16, 2015
Provisional Application 62232067 · Sep 24, 2015
Related Publication 20190071717A1 · Mar 7, 2019
Cited By (9)
US 12,264,323 US 12,264,359 US 12,344,838 US 12,371,737 US 12,410,416 US 12,410,468 US 12,415,994 US 12,534,715 US 12,686,862